Use of ifn-i activity as a biomarker for tlr inhibitor treatment
AssigneeMerck Patent GmbH
InventorsJamie Shaw, Andrew Bender, Ankita Deshmukh, Bharat Vaidyanathan
Life of this patent
Estimating the term…
Abstract
The present invention provides for the use of IFN-I activity as a predictive biomarker for the treatment of patients with toll-like receptor (TLR) inhibitors and related uses and methods.
Claims18
Use of the IFN-I activity as a predictive biomarker for the TLR inhibitor treatment of an individual with a disease;
- wherein the TLR inhibitor is a TLR7 and/or TLR8 small molecule inhibitor.
A method for predicting therapeutic effectiveness of a TLR inhibitor in an individual with a disease comprising determining the IFN-I activity in a sample from the individual,
- wherein the IFN-I activity in the sample indicates the therapeutic effectiveness of the TLR inhibitor;
- and
- wherein the TLR inhibitor is a TLR7 and/or TLR8 small molecule inhibitor.
A method for predicting the suitability of an individual with a disease to initiate treatment with a TLR inhibitor comprising determining the IFN-I activity in a sample from the individual,
- wherein the IFN-I activity in the sample indicates the suitability of the individual to initiate the treatment;
- and
- wherein the TLR inhibitor is a TLR7 and/or TLR8 small molecule inhibitor.
A method for predicting the suitability of an individual with a disease who is receiving treatment with a TLR inhibitor to continue said treatment comprising determining the IFN-I activity in a sample from the individual,
- wherein the IFN-I activity in the sample indicates the suitability of the individual to continue the treatment;
- and
- wherein the TLR inhibitor is a TLR7 and/or TLR8 small molecule inhibitor.
A TLR inhibitor for use in a method of treating a disease in an individual comprising administering the TLR inhibitor to the individual,
- wherein treatment is based upon IFN-I acitivity in a sample from the individual;
- and
- wherein the TLR inhibitor is a TLR7 and/or TLR8 small molecule inhibitor.
A TLR7 and/or TLR8 inhibitor and a glucocorticosteroid for use in a method of treating a disease in an individual having high IFN-I activity, wherein the method comprises administering the TLR7 and/or TLR8 inhibitor in combination with the glucocorticosteroid to the individual.
Dependencies are inferred from the claim text.